NEO 377

Drug Profile

NEO 377

Latest Information Update: 02 Jul 2003

Price : $50

At a glance

  • Originator Spectrum Pharmaceuticals
  • Class Antipsychotics
  • Mechanism of Action Dopamine receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 02 Jul 2003 Discontinued - Preclinical for Schizophrenia in USA (unspecified route)
  • 02 Jul 2003 NEO 377 is available for licensing (http://www.spectrumpharm.com)
  • 17 Dec 2002 NeoTherapeutics is now called Spectrum Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top